← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sir Mortimer B. Davis Jewish Gen Hosp
Montreal, PQ
$5,332,747
Total funding
7
Grants
Funding over time
peak $802.8K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,332,747 · 7
By mechanism
R01$4,595,648 · 5
U10$441,653 · 1
R21$295,446 · 1
Investigators at Sir Mortimer B. Davis Jewish Gen Hosp
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Development of the Gag/Lysyl tRNA synthetase interaction as a target for anti-HIV$662,810
R01 · FY2008 · AI
Development of the Gag/Lysyl tRNA synthetase interaction as a target for anti-HIV$616,301
R01 · FY2010 · AI
Development of the Gag/Lysyl tRNA synthetase interaction as a target for anti-HIV$612,285
R01 · FY2009 · AI
Development of the Gag/Lysyl tRNA synthetase interaction as a target for anti-HIV$606,793
R01 · FY2012 · AI
Development of the Gag/Lysyl tRNA synthetase interaction as a target for anti-HIV$596,085
R01 · FY2011 · AI
Role of Lysyl-tRNA Synthetase in HIV-1 Replication$259,490
R01 · FY2005 · AI
Role of Lysyl-tRNA Synthetase in HIV-1 Replication$259,219
R01 · FY2004 · AI
Role of Lysyl-tRNA Synthetase in HIV-1 Replication$253,675
R01 · FY2006 · AI
DELETION MUTAGENESIS WITHIN NONCODING SEGMENTS OF HIV1$195,299
R01 · FY2000 · AI
The role of LXR/RXR heterodimers in arsenic-induced atherosclerosis.$158,674
R21 · FY2009 · ES
Tricyclic antidepressants as risks factors for cancer$140,289
R01 · FY2001 · CA
The role of LXR/RXR heterodimers in arsenic-induced atherosclerosis.$136,772
R21 · FY2010 · ES
Lysyl-tRNA Synthetase in HIV-1 Replication$130,475
R01 · FY2003 · AI
Tricyclic antidepressants as risks factors for cancer$87,927
R01 · FY2002 · CA
DELETION MUTAGENESIS WITHIN NONCODING SEGMENTS OF HIV1$75,000
R01 · FY2001 · AI
Silibinin in Prostate Cancer Chemoprevention &Treatment$50,000
R01 · FY2004 · CA
Silibinin in Prostate Cancer Chemoprevention &Treatment$50,000
R01 · FY2003 · CA
PRIMARY BREAST CANCER THERAPY GROUP$35,625
U10 · FY2003 · CA
PRIMARY BREAST CANCER THERAPY GROUP$35,625
U10 · FY2004 · CA
PRIMARY BREAST CANCER THERAPY GROUP$35,625
U10 · FY2002 · CA